Condition: Non Squamous Non Small Cell Lung Cancer · Sponsor: CrystalGenomics, Inc.
The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed advanced or metastatic (Stage IIIB-IV), EGFR/ALK wild-type, non-squamous, non-small cell lung cancer. In this study, subjects with advanced or metastatic, EGFR/ALK wild-type, non-squamous, non-small lung cancer will receive anti-PD-1 antibody therapy of camrelizumab in combination with pemetrexed + carboplatin as first-line treatment for at least 8 cycles (24 weeks). Then, the best overall RECIST responses (BOR) from subjects who have had at least 1 post-baseline tumor assessment will be evaluated to confirm that camrelizumab, a drug that has already been approved China, has similar efficacy in the Korean population as in the Chinese population.
This description comes directly from the study's public registry record.
Kyung Hye Kim · +821087370206 · khkim@cgxinc.com
Always discuss trial participation with your own doctor first.
| Korea University Anam Hospital | Anam, South Korea | Recruiting |
| Hallym University Sacred Heart Hospital | Anyang, South Korea | Recruiting |
| Chonnam National University Hwasun Hospital | Hwasun, South Korea | Recruiting |
| Catholic University of Korea EunPyeong St. Mary's Hospital | Seoul, South Korea | Recruiting |
| Catholic University of Korea Yeouido St. Mary's Hospital | Seoul, South Korea | Recruiting |
| Korea University Guro Hospital | Seoul, South Korea | Recruiting |
| Seoul Asan Hospital | Seoul, South Korea | Recruiting |
| Busan National University Hospital Yangsan | Yangsan, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05841472